Lantern Pharma Inc.
LTRN
$3.16
-$0.03-0.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.36% | -30.19% | -25.96% | -24.46% | -25.19% |
| Total Depreciation and Amortization | 12.71% | -14.47% | 73.15% | 44.76% | 17.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -50.42% | -34.55% | -114.33% | -78.58% | -55.38% |
| Change in Net Operating Assets | -94.28% | 314.16% | 4,488.49% | 223.90% | 360.68% |
| Cash from Operations | -39.99% | -24.16% | -26.39% | -8.54% | -3.49% |
| Capital Expenditure | 4.13% | 32.98% | 29.47% | 27.43% | 67.12% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,497.82% | 471.07% | 134.27% | 70.71% | 44.29% |
| Cash from Investing | 1,463.43% | 462.21% | 130.54% | 69.60% | 45.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -78.06% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 102.69% | 113.34% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -11.14% | -74.30% | 194.16% | -354.10% | -85.47% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18.29% | 8.72% | -22.78% | -7.02% | -3.45% |